Biomarkers as tools for improved diagnostic and therapeutic monitoring in systemic lupus erythematosis

Arthritis Research and Therapy

Volumn 11, Issue 6, 2009, Pages

  Smith Jr, Michael F ^a,b   Hiepe, Falk ^c   Dörner, Thomas ^c   Burmester, Gerd ^c  

^a PFIZER INC   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; CARDIOLIPIN ANTIBODY; CD27 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA DQ1 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RITUXIMAB; SIALOADHESIN; SOLUBLE INTERLEUKIN 2 RECEPTOR;

AUTOIMMUNE THROMBOCYTOPENIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG DEVELOPMENT; EUROPE; FOOD AND DRUG ADMINISTRATION; HUMAN; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; MEMORY CELL; NONHUMAN; OUTCOME ASSESSMENT; PHOTOSENSITIVITY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; IMMUNOLOGY;

BIOLOGICAL MARKERS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 77952476575     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2834     Document Type: Review

References (53)

1. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277. 10.1002/art.1780251101, 7138600.
2. Merrill JT, Erkan D, Buyon JP. Challenges in bringing the bench to bedside in drug development for SLE. Nat Rev Drug Discov 2004, 3:1036-1046. 10.1038/nrd1577, 15573102.
3. Petri M. Disease activity assessment in SLE: do we have the right instruments?. Ann Rheum Dis 2007, 66(Suppl 3):iii61-iii64. 10.1136/ard.2007.078477, 17934099.
4. Guidance for Industry: Systemic Lupus Erythematosus-Developing Drugs for Treatment. , http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdf
5. Liu CC, Manzi S, Ahearn JM. Biomarkers for systemic lupus erythematosus: a review and perspective. Curr Opin Rheumatol 2005, 17:543-549. 10.1097/01.bor.0000174182.70159.22, 16093831.
6. ClinicalTrials.gov. , http://www.clinicaltrials.gov
7. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 2004, 50:1709-1720. 10.1002/art.20344, 15188346.
8. Chung SA, Tian C, Taylor KE, Lee AT, Ortmann WA, Hom G, Graham RR, Nititham J, Kelly JA, Morrisey J, Wu H, Yin H, Alarcon-Riquelme ME, Tsao BP, Harley JB, Gaffney PM, Moser KL, Manzi S, Petri M, Gregersen PK, Langefeld CD, Behrens TW, Seldin MF, Criswell LA. European population substructure is associated with mucocutaneous manifestations and autoanti-body production in systemic lupus erythematosus. Arthritis Rheum 2009, 60:2448-2456. 2739103, 19644962, 10.1002/art.24707.
9. Harley JB, Sestak AL, Willis LG, Fu SM, Hansen JA, Reichlin M. A model for disease heterogeneity in systemic lupus erythematosus. Relationships between histocompatibility antigens, autoantibodies, and lymphopenia or renal disease. Arthritis Rheum 1989, 32:826-836.
10. Riemekasten G, Marell J, Trebeljahr G, Klein R, Hausdorf G, Haupl T, Schneider-Mergener J, Burmester GR, Hiepe F. A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. J Clin Invest 1998, 102:754-763. 508938, 9710444, 10.1172/JCI2749.
11. Shoenfeld N, Agmon-Levin N, Flitman-Katzevman I, Paran D, Katz BS, Kivity S, Langevitz P, Zandman-Goddard G, Shoenfeld Y. The sense of smell in systemic lupus erythematosus. Arthritis Rheum 2009, 60:1484-1487. 10.1002/art.24491, 19404932.
12. Krause I, Blank M, Fraser A, Lorber M, Stojanovich L, Rovensky J, Shoenfeld Y. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology 2005, 210:749-754. 10.1016/j.imbio.2005.10.005, 16325493.
13. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533. 10.1056/NEJMoa021933, 14561795.
14. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979, 301:5-8.
15. Vallin H, Blomberg S, Alm GV, Cederblad B, Rönnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999, 115:196-202. 1905199, 9933442, 10.1046/j.1365-2249.1999.00772.x.
16. Vallin H, Perers A, Alm GV, Rönnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol 1999, 163:6306-6313.
17. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294:1540-1543. 10.1126/science.1064890, 11711679.
18. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100:2610-2615. 151388, 12604793, 10.1073/pnas.0337679100.
19. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723. 2193846, 12642603, 10.1084/jem.20021553.
20. Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003, 36:481-490. 10.1080/08916930310001625952, 14984025.
21. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003, 4:177-186. 10.1038/sj.gene.6363966, 12700592.
22. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, Ly N, Woodward RN, Fry KE, Lau AY, Prentice JG, Wohlgemuth JG, Crow MK. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004, 50:3958-3967. 10.1002/art.20798, 15593221.
23. Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythematosus. Ann Rheum Dis 2008, 67:1069-1075. 10.1136/ard.2007.074765, 18063674.
24. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, Stichweh D, Blankenship D, Li L, Munagala I, Bennett L, Allantaz F, Mejias A, Ardura M, Kaizer E, Monnet L, Allman W, Randall H, Johnson D, Lanier A, Punaro M, Wittkowski KM, White P, Fay J, Klintmalm G, Ramilo O, Palucka AK, Banchereau J, Pascual V. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008, 29:150-164. 2727981, 18631455, 10.1016/j.immuni.2008.05.012.
25. Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, Espe KJ, Li W, Patel DD, Gregersen PK, Behrens TW. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006, 3:e491. 1702557, 17177599, 10.1371/journal.pmed.0030491.
26. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005, 52:1491-1503. 10.1002/art.21031, 15880830.
27. Biesen R, Demir C, Barkhudarova F, Grun JR, Steinbrich-Zollner M, Backhaus M, Haupl T, Rudwaleit M, Riemekasten G, Radbruch A, Hiepe F, Burmester GR, Grutzkau A. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 2008, 58:1136-1145. 10.1002/art.23404, 18383365.
28. Yao Y, Richman L, Higgs BW, Morehouse CA, de Los Reyes M, Brohawn P, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009, 60:1785-1796. 10.1002/art.24557, 19479852.
29. Bauer JW, Petri M, Batliwalla F, Wilson JC, Koeuth T, Singh S, Tesfasyone H, Gregersen PK, Behrens TW, Baechler EC. Baseline IFN-regulated chemokine levels are strong predictors of systemic lupus erythematosus flare [abstract]. Arthritis Rheum 2008, 58(9 Suppl):S805.
30. Campen DH, Horwitz DA, Quismorio FP, Ehresmann GR, Martin WJ. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum 1988, 31:1358-1364. 10.1002/art.1780311103, 3263865.
31. Semenzato G, Bambara LM, Biasi D, Frigo A, Vinante F, Zuppini B, Trentin L, Feruglio C, Chilosi M, Pizzolo G. Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. J Clin Immunol 1988, 8:447-452. 10.1007/BF00916949, 3065351.
32. Wolf RE, Brelsford WG. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum 1988, 31:729-735. 10.1002/art.1780310605, 3132927.
33. Swaak AJ, Hintzen RQ, Huysen V, Brink HG, Smeenk JT. Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course. Clin Rheumatol 1995, 14:293-300. 10.1007/BF02208342, 7641505.
34. Kato K, Santana-Sahagun E, Rassenti LZ, Weisman MH, Tamura N, Kobayashi S, Hashimoto H, Kipps TJ. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999, 104:947-955. 408556, 10510335, 10.1172/JCI7014.
35. Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC. Serum IL-6, TNFα, p55 srTNFα, p75srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 1999, 18:17-22. 10.1007/s100670050045, 10088943.
36. ter Borg EJ, Horst G, Limburg PC, Kallenberg CG. Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus. Clin Exp Immunol 1990, 82:21-26. 1535173, 2208793.
37. Khare SD, Sarosi I, Xia XZ, McCabe S, Miner K, Solovyev I, Hawkins N, Kelley M, Chang D, Van G, Ross L, Delaney J, Wang L, Lacey D, Boyle WJ, Hsu H. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000, 97:3370-3375. 16246, 10716715, 10.1073/pnas.050580697.
38. Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006, 15:570-576. 10.1177/0961203306071871, 17080911.
39. Ju S, Zhang D, Wang Y, Ni H, Kong X, Zhong R. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem 2006, 39:1131-1137. 10.1016/j.clinbiochem.2006.09.010, 17069785.
40. Lin Z, Dan-Rong Y, Xiao-Qing T, Hao W, Hong-Lian G, Xian-Tao K, Ren-Qian Z, Jiyu L. Preliminary clinical measurement of the expression of B-cell activating factor in Chinese systemic lupus erythematosus patients. J Clin Lab Anal 2007, 21:183-187. 10.1002/jcla.20161, 17506477.
41. Morimoto S, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, Nakiri Y, Suzuki J, Nozawa K, Amano H, Tokano Y, Kobata T, Takasaki Y. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Rheumatology (Oxford) 2007, 46:1083-1086. 10.1093/rheumatology/kem097, 17500077.
42. Stohl W. SLE - systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther 2003, 5:136-138. 165050, 12723979, 10.1186/ar755.
43. Lindh E, Lind SM, Lindmark E, Hassler S, Perheentupa J, Peltonen L, Winqvist O, Karlsson MC. AIRE regulates T-cell-independent B-cell responses through BAFF. Proc Natl Acad Sci USA 2008, 105:18466-18471. 2587634, 19011083, 10.1073/pnas.0808205105.
44. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006, 8:R6. 1526545, 16356193, 10.1186/ar1855.
45. Emmerich F, Bal G, Barakat A, Milz J, Muhle C, Martinez-Gamboa L, Dorner T, Salama A. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007, 136:309-314. 10.1111/j.1365-2141.2006.06431.x, 17156395.
46. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005, 52:501-513. 10.1002/art.20858, 15693003.
47. Hutloff A, Buchner K, Reiter K, Baelde HJ, Odendahl M, Jacobi A, Dorner T, Kroczek RA. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum 2004, 50:3211-3220. 10.1002/art.20519, 15476242.
48. Yang JH, Zhang J, Cai Q, Zhao DB, Wang J, Guo PE, Liu L, Han XH, Shen Q. Expression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44:1245-1254. 10.1093/rheumatology/keh724, 15987711.
49. Hartnell A, Steel J, Turley H, Jones M, Jackson DG, Crocker PR. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood 2001, 97:288-296. 10.1182/blood.V97.1.288, 11133773.
50. Berg TK, Nath D, Ziltener HJ, Vestweber D, Fukuda M, van Die I, Crocker PR. Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1). J Immunol 2001, 166:3637-3640.
51. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, Valet G, Lipsky PE, Dorner T. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:1332-1342. 10.1002/art.10949, 12746906.
52. Jacobi AM, Reiter K, Mackay M, Aranow C, Hiepe F, Radbruch A, Hansen A, Burmester GR, Diamond B, Lipsky PE, Dorner T. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008, 58:1762-1773. 10.1002/art.23498, 18512812.
53. Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, Lee EH, Milner EC, Sanz I. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007, 178:6624-6633.